Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis

European Journal of Medicinal Chemistry

Volumn 47, Issue 1, 2012, Pages 1-17

  Wetzel, Marie ^a   Gargano, Emanuele M ^a   Hinsberger, Stefan ^b   Marchais Oberwinkler, Sandrine ^a   Hartmann, Rolf W ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

17 HSD2; Non steroidal inhibitors; Osteoporosis; Steroidomimetics

Indexed keywords

(2' CHLORO 4' HYDROXYBIPHENYL 4 YL) (3 HYDROXYPHENYL) METHANONE; (3 BROMOPHENYL) 3 METHOXYPHENYL) METHANOL; (3 BROMOPHENYL) 3 METHOXYPHENYL) METHANONE; (3 FLUORO 5 HYDROXYPHENYL) (4' HYDROXY 3' METHYLBIPHENYL 4 YL) METHANONE; (3 HYDROXY 4 METHYLPHENYL) [6 (4 HYDROXY 3 METHYLPHENYL) PYRIDIN 2 YL] METHANONE; (3 HYDROXYPHENYL) [6 (3 HYDROXYPHENYL) PYRIDIN 2 YL] METHANONE; (3' CHLORO 4' HYDROXYBIPHENYL 4 YL) (3 HYDROXYPHENYL) METHANONE; (3' CHLORO 4' HYDROXYBIPHENYL 4 YL) (4 FLUORO 3 HYDROXYPHENYL) METHANONE; (3,4 DIFLUOROPHENYL) (4 HYDROXY 3' METHYLBIPHENYL 4 YL) METHANONE; (4 BROMOPHENYL) (3 METHOXYPHENYL) METHANOL; (4 BROMOPHENYL) (3 METHOXYPHENYL) METHANONE; (4 FLUORO 3 HYDROXYPHENYL) (4' HYDROXY 3' METHYLBIPHENYL 4 YL) METHANONE; (4 FLUORO 3 HYDROXYPHENYL) [5 (4 HYDROXY 3 METHOXYPHENYL) PYRIDIN 2 YL] METHANONE; (4 FLUORO 3 HYDROXYPHENYL) [5 (CHLORO 4 HYDROXYPHENYL) PYRIDIN 2 YL] METHANONE; (4 FLUORO 3 HYDROXYPHENYL) [6 (4 HYDROXY 3 METHYLPHENYL) PYRIDIN 2 YL] METHANONE; (4' HYDROXY 3' METHYLBIPHENYL 3' YL) (3 HYDROXYPHENYL) METHANONE; (4' METHOXY 3' METHYLBIPHENYL 3 YL) (3 METHOXYPHENYL) METHANONE; (4' METHOXY 3' METHYLBIPHENYL 4 YL) (3 METHOXYPHENYL) METHANONE; 17BETA HYDROXYSTEROID DEHYDROGENASE 2 INHIBITOR; [5 (4 HYDROXY 3 METHYLPHENYL) PYRIDIN 2 YL] (3 HYDROXYPHENYL) METHANONE; [6 (3 CHLORO 4 HYDROXYPHENYL) PYRIDIN 2 YL] 3 HYDROXYPHENYL) METHANONE; [6 (4 HYDROXY 3 METHYLPHENYL) PYRIDIN 2 YL] (3 HYDROXYPHENYL) METHANONE; [6 (4 HYDROXY 3 METHYLPHENYL) PYRIDIN 3 YL] (3 HYDROXYPHENYL) METHANONE; ESTRADIOL; ESTRONE; HYDROXYPHENYLMETHANONE DERIVATIVE; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CATALYSIS; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OSTEOPOROSIS; SUBSTITUTION REACTION;

BENZOPHENONES; DRUG DISCOVERY; ENZYME INHIBITORS; ESTRADIOL DEHYDROGENASES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OSTEOPOROSIS; RECEPTORS, ESTROGEN;

EID: 84855799481     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.09.004     Document Type: Article

References (52)

1. J.E. Compston Sex steroids and bone Physiol. Rev. 81 2001 419 447
2. U.A. Liberman, S.R. Weiss, J. Bröll, H.W. Minne, H. Quan, N.H. Bell, J. Rodriguez-Portales, R.W. Downs Jr. , J. Dequeker, M. Favus, E. Seeman, R.R. Recker, T. Capizzi, A.C.I. Santora, A. Lombardi, R.V. Shah, L.J. Hirsch, and D.B. Karpf Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N. Engl. J. Med. 333 1995 1437 1443
3. D.C. Bauer, D.M. Black, P. Garnero, M. Hochberg, S. Ott, J. Orloff, D.E. Thompson, S.K. Ewing, and P.D. Delmas Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J. Bone Miner. Res. 19 2004 1250 1258
4. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, and A. Lombardi Alendronate for the treatment of osteoporosis in men N. Engl. J. Med. 343 2000 604 610
5. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, C. Christiansen, P.D. Delmas, J.R. Zanchetta, J. Stakkestad, C.C. Glüer, K. Krueger, F.J. Cohen, S. Eckert, K.E. Ensrud, L.V. Avioli, P. Lips, and S.R. Cummings Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
6. E. Barrett-Connor, L. Mosca, P. Collins, M.J. Geiger, D. Grady, M. Kornitzer, M.A. McNabb, and N.K. Wenger Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N. Engl. J. Med. 355 2006 125 137
7. R. Rizzoli, U. Yasothan, and P. Kirkpatrick Denosumab Nat. Rev. Drug Discov. 9 2010 591 592
8. M. McClung Role of RANKL inhibition in osteoporosis Arthritis Res. Ther. 9 Suppl. 1 2007 3
9. S. Boonen, J.D. Adachi, Z. Man, S.R. Cummings, K. Lippuner, O. Törring, J.C. Gallagher, J. Farrerons, A. Wang, N. Franchimont, J. San Martin, A. Grauer, and M. McClung Treatment with Denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk J. Clin. Endocrinol. Metab. 96 2011 1727 1736
10. R.T. Turner, B.L. Riggs, and T.C. Spelsberg Skeletal effects of estrogen Endocr. Rev. 15 1994 275 300
11. E.F. Eriksen Cellular mechanisms of bone remodeling Rev. Endocr. Metab. Disord. 11 2010 219 227
12. A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio, and H. Ozawa Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin Biochem. Biophys. Res. Commun. 247 1998 610 615
13. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, and W.S. Simonet Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev. 12 1998 1260 1268
14. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle, and J.M. Penninger OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
15. Y. Dong, Q.Q. Qiu, J. Debear, W.F. Lathrop, D.R. Bertolini, and P.P. Tamburini 17Beta-hydroxysteroid dehydrogenases in human bone cells J. Bone Miner. Res. 13 1998 1539 1546
16. A. Cavalli, A. Bisi, C. Bertucci, C. Rosini, A. Paluszcak, S. Gobbi, E. Giorgio, A. Rampa, F. Belluti, L. Piazzi, P. Valenti, R.W. Hartmann, and M. Recanatini Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach J. Med. Chem. 48 2005 7282 7289
17. M.P. Leze, M. Le Borgne, P. Pinson, A. Palusczak, M. Duflos, G. Le Baut, and R.W. Hartmann Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol- 1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors Bioorg. Med. Chem. Lett. 16 2006 1134 1137
18. S. Gobbi, A. Cavalli, M. Negri, K.E. Schewe, F. Belluti, L. Piazzi, R.W. Hartmann, M. Recanatini, and A. Bisi Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 50 2007 3420 3422
19. S. Haidar, P.B. Ehmer, S. Barassin, C. Batzl-Hartmann, and R.W. Hartmann Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo J. Steroid Biochem. Mol. Biol. 84 2003 555 562
20. F. Leroux, T.U. Hutschenreuter, C. Charrire, R. Scopelliti, and R.W. Hartmann N-(4-biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv. Chim. Acta 86 2003 2671 2686
21. C. Jagusch, M. Negri, U.E. Hille, Q. Hu, M. Bartels, K. Jahn-Hoffmann, M.A. Pinto-Bazurco Mendieta, B. Rodenwaldt, U. Müller-Vieira, D. Schmidt, T. Lauterbach, M. Recanatini, A. Cavalli, and R.W. Hartmann Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure Bioorg. Med. Chem. 16 2008 1992 2010
22. U.E. Hille, Q. Hu, C. Vock, M. Negri, M. Bartels, U. Müller-Vieira, T. Lauterbach, and R.W. Hartmann Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 44 2009 2765 2775
23. E. Baston, and R.W. Hartmann N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity Bioorg. Med. Chem. Lett. 9 1999 1601 1606
24. F. Picard, E. Baston, W. Reichert, and R.W. Hartmann Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 8 2000 1479 1487
25. E. Baston, A. Palusczak, and R.W. Hartmann 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2 Eur. J. Med. Chem. 35 2000 931 940
26. M. Frotscher, E. Ziegler, S. Marchais-Oberwinkler, P. Kruchten, A. Neugebauer, L. Fetzer, C. Scherer, U. Müller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 51 2008 2158 2169
27. S. Marchais-Oberwinkler, P. Kruchten, M. Frotscher, E. Ziegler, A. Neugebauer, U. Bhoga, E. Bey, U. Müller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics J. Med. Chem. 51 2008 4685 4698
28. E. Bey, S. Marchais-Oberwinkler, P. Kruchten, M. Frotscher, R. Werth, A. Oster, O. Algül, A. Neugebauer, and R.W. Hartmann Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 16 2008 6423 6435
29. E. Bey, S. Marchais-Oberwinkler, R. Werth, M. Negri, Y.A. Al-Soud, P. Kruchten, A. Oster, M. Frotscher, B. Birk, and R.W. Hartmann Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) J. Med. Chem. 51 2008 6725 6739
30. E. Bey, S. Marchais-Oberwinkler, M. Negri, P. Kruchten, A. Oster, T. Klein, A. Spadaro, R. Werth, M. Frotscher, B. Birk, and R.W. Hartmann New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity J. Med. Chem. 52 2009 6724 6743
31. A. Oster, T. Klein, R. Werth, P. Kruchten, E. Bey, M. Negri, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Novel estrone mimetics with high 17beta-HSD1 inhibitory activity Bioorg. Med. Chem. 18 2010 3494 3505
32. A. Oster, S. Hinsberger, R. Werth, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 53 2010 8176 8186
33. A. Oster, T. Klein, C. Henn, R. Werth, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1): the role of the bicyclic moiety ChemMedChem 6 2011 476 487
34. S. Marchais-Oberwinkler, M. Wetzel, E. Ziegler, P. Kruchten, R. Werth, C. Henn, R.W. Hartmann, and M. Frotscher New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases J. Med. Chem. 54 2011 534 547
35. K. Sam, F. Labrie, and D. Poirier N-Butyl-N-methyl-11-(3′-hydroxy- 21′, 17′-carbolactone-19′-nor-17′alpha-pregna-1′, 3′, 5′(10′)-trien-7′alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity Eur. J. Med. Chem. 35 2000 217 225
36. D. Poirier, P. Bydal, M.R. Tremblay, K.M. Sam, and V. Luu-The Inhibitors of type II 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 171 2001 119 128
37. P. Bydal, S. Auger, and D. Poirier Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships Steroids 69 2004 325 342
38. J. Wood, C.M. Bagi, C. Akuche, A. Bacchiocchi, J. Baryza, M.L. Blue, C. Brennan, A.M. Campbell, S. Choi, J.H. Cook, P. Conrad, B.R. Dixon, P.P. Ehrlich, T. Gane, D. Gunn, T. Joe, J.S. Johnson, J. Jordan, R. Kramss, P. Liu, J. Levy, D.B. Lowe, I. McAlexander, R. Natero, A.M. Redman, W.J. Scott, C. Town, M. Wang, Y. Wang, and Z. Zhang 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate Bioorg. Med. Chem. Lett. 16 2006 4965 4968
39. S. Marchais-Oberwinkler, C. Henn, G. Möller, T. Klein, M. Negri, A. Oster, A. Spadaro, R. Werth, M. Wetzel, K. Xu, M. Frotscher, R.W. Hartmann, and J. Adamski 17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 2011
40. M. Wetzel, S. Marchais-Oberwinkler, and R.W. Hartmann 17beta-HSD2 inhibitors for the treatment of osteoporosis: identification of a promising scaffold Bioorg. Med. Chem. 19 2011 807 815
41. C.M. Bagi, J. Wood, D. Wilkie, and B. Dixon Effect of 17beta-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys J. Musculoskelet. Neuronal Interact. 8 2008 267 280
42. N. Miyaura, and A. Suzuki Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 95 1995 2457 2483
43. M.V. Bhatt, and S.U. Kulkarni Cleavage of ethers Synthesis 1983 1983 249 282
44. K.M. Sam, S. Auger, V. Luu-The, and D. Poirier Steroidal spiro-gamma-lactones that inhibit 17beta-hydroxysteroid dehydrogenase activity in human placental microsomes J. Med. Chem. 38 1995 4518 4528
45. W. Qiu, R.L. Campbell, A. Gangloff, P. Dupuis, R.P. Boivin, M.R. Tremblay, D. Poirier, and S.X. Lin A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity Faseb J. 16 2002 1829 1831
46. P. Kruchten, R. Werth, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents Mol. Cell. Endocrinol. 301 2009 154 157
47. Y.A. Al-Soud, E. Bey, A. Oster, S. Marchais-Oberwinkler, R. Werth, P. Kruchten, M. Frotscher, and R.W. Hartmann The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2 Mol. Cell. Endocrinol. 301 2009 212 215
48. S.X. Lin, F. Yang, J.Z. Jin, R. Breton, D.W. Zhu, V. Luu-The, and F. Labrie Subunit identity of the dimeric 17 beta-hydroxysteroid dehydrogenase from human placenta J. Biol. Chem. 267 1992 16182 16187
49. + J. Mol. Biol. 234 1993 242 244
50. K.M. Sam, R.P. Boivin, M.R. Tremblay, S. Auger, and D. Poirier C16 and C17 derivatives of estradiol as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discov. 15 1998 157 180
51. J. Zimmermann, R. Liebl, and E. von Angerer 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha J. Steroid Biochem. Mol. Biol. 94 2005 57 66
52. R.W. Hartmann Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxyphenyl)ethane estrogens and antiestrogens J. Med. Chem. 29 1986 1668 1674